(Q36295107)

13 August 2017

Advances in Breast Cancer - Looking Back over the Year (English)

1 reference

13 August 2017

6

P A Fasching

1 reference

13 August 2017

2

M P Lux

1 reference

13 August 2017

D Lüftner

1

1 reference

13 August 2017

N Maass

3

1 reference

13 August 2017

F Schütz

4

1 reference

13 August 2017

I Schwidde

5

1 reference

13 August 2017

T Fehm

7

1 reference

13 August 2017

W Janni

8

1 reference

13 August 2017

S Kümmel

9

1 reference

13 August 2017

H-C Kolberg

10

1 reference

13 August 2017

1 December 2012

1 reference

Geburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die Praxis

13 August 2017

1 reference

13 August 2017

72

1 reference

13 August 2017

12

1 reference

13 August 2017

1117-1129

1 reference

Biomarkers in Breast Cancer - An Update

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Health Services Research and Health Economy - Quality Care Training in Gynaecology, with Focus On Gynaecological Oncology

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Breast Cancer 2012 - New Aspects

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Breast Cancer Risk - Genes, Environment and Clinics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Evolution of the cancer genome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Comprehensive molecular portraits of human breast tumours

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Whole-genome analysis informs breast cancer response to aromatase inhibition

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Invasive Breast Cancer: Recognition of Molecular Subtypes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Risk factors for brain relapse in HER2-positive metastatic breast cancer patients.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651151

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NC

22 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26640285

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Circulating Tumor Cells in Early-Stage Breast Cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26640285

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1055/S-0032-1328084

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

26640285

1 reference